KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Amneal Pharmaceuticals (AMRX) Long-Term Debt Repayments (2017 - 2026)

Amneal Pharmaceuticals has reported Long-Term Debt Repayments over the past 8 years, most recently at -$5.6 billion for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments fell 1642.75% year-over-year to -$5.6 billion; the TTM value through Dec 2025 reached -$2.8 billion, down 1357.36%, while the annual FY2025 figure was -$2.8 billion, 1388.22% down from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was -$5.6 billion at Amneal Pharmaceuticals, down from $2.6 billion in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $2.6 billion in Q3 2025 and troughed at -$5.6 billion in Q4 2025.
  • A 5-year average of -$209.2 million and a median of $13.5 million in 2024 define the central range for Long-Term Debt Repayments.
  • On a YoY basis, Long-Term Debt Repayments climbed as much as 4586.29% in 2025 and fell as far as 1642.75% in 2025.
  • Year by year, Long-Term Debt Repayments stood at -$146.3 million in 2021, then tumbled by 56.42% to -$228.9 million in 2022, then plummeted by 147.1% to -$565.6 million in 2023, then soared by 43.02% to -$322.3 million in 2024, then plummeted by 1642.75% to -$5.6 billion in 2025.
  • Business Quant data shows Long-Term Debt Repayments for AMRX at -$5.6 billion in Q4 2025, $2.6 billion in Q3 2025, and $15.5 million in Q2 2025.